Design Highlights
- Medicare’s GLP-1 Bridge Program allows seniors with specific BMI criteria to access weight-loss medications at reduced costs.
- Eligible drugs include Wegovy, Foundayo, and Zepbound KwikPen, with limited coverage options.
- Enrollment in Medicare Part D and provider attestation are required for program participation.
- The program is active until December 31, 2027, creating uncertainty for future coverage.
- Manufacturers receive approximately $245 monthly per covered drug, helping manage overall healthcare costs.
But before anyone gets too excited, there’s a catch. You need to be enrolled in Medicare Part D and meet some clinical criteria, which can feel like jumping through hoops. You must be at least 18 years old and meet specific BMI thresholds. If your BMI is 35 or higher, congratulations, you’re in! If it’s 30 or higher but you’re also dealing with heart failure or uncontrolled hypertension, you might just qualify, too. And don’t forget, no one gets a pass without provider attestation. Nothing like a little red tape to spice things up.
The covered drugs are limited to selected GLP-1s that are approved for weight reduction. That means if you were hoping for a buffet of options, think again. Only certain formulations of Wegovy, Foundayo, and Zepbound KwikPen are on the menu. It’s a tight list, and if your favorite isn’t included, well, tough luck! The Bridge program is only active through December 31, 2027, and future coverage options remain uncertain for patients.
The manufacturers will feel the love, too, receiving around $245 per month for these drugs. A nice arrangement that aims to keep costs down while savoring some savings on federal spending. That’s right; it’s all about managing the budget while giving seniors a fighting chance. The increased utilization of these medications reflects a broader trend, as specialty drug costs have been identified as a key driver of rising healthcare premiums across the industry. Additionally, while the Medicare GLP-1 Bridge provides access through 2027, the uncertainty around future Medicare coverage remains a concern for many.
